Downloads
Abstract
Overview: Vitamin K antagonists (VKAs) are the most commonly used to prevent thrombotic and embolic
complications associated with atrial fibrillation, mechanical valves and deep vein thrombosis. However,
the narrow therapeutic window, food and drug interactions are their limitations. The efficacy and safety of
these drugs depend on the International Normalized Ratio (INR). Time in Therapeutic Range (TTR) is a
parameter that reflects the effectiveness of VKAs over time.
Objectives: The study aimed to evaluate of time in therapeutic range with vitamin K antagonists. Subjects and research methods: Cross-sectional research included 301 patients being treated for VKAs at Dong Nai General Hospital from 12/2018 to 09/2019 and TTR was evaluated by Rosendaal methods.
Results: The mean age was 61.6 ± 12.1 years, women accounted for 56.1%. Atrial fibrillation without heart valve disease accounted for 44.8%, mechanical valve accounted for 31.2%; Atrial fibrillation / moderate mitral stenosis accounted for 14%. The average dose of Acenocoumarol was 10.9 ± 4.3mg / week, the average INR test interval was 26 days Time in the therapeutic range (TTR) 40.3 ± 22.2. The INR ratio in the therapeutic threshold (FIR) was 41.6 ± 22. The mechanical valve group had a higher TTR than that of the atrial fibrillation group (42.6 ± 23.6 with 38.7 ± 20.4).
Conclusion: Patients on VKAs have low TTR. In order to improve the quality of treatment, patients should be closely monitored, adequately educated for diet restrictions , and drug interactions. An anticoagulation patient club should be established. Anticoagulation clinics should be organized.
References
Hướng dẫn thực hành xử trí biến cố chảy máu khi dùng thuốc chống đông đường uống 2018, Hội Tim mạch học quốc gia Việt Nam.
Huỳnh Thanh Kiều và cs (2015), khảo sát thời gian INR trong khoảng điều trị của người bệnh đang điều trị thuốc kháng vitamin K tại phòng khám Bệnh viện Tâm Đức. Chuyên đề Tim mạch học http://timmachhoc.vn/ tong-hop-tu-nghien-cuu-tren-lam-sang/1164- khao-sat-thoi-gian-inr-trong-khoang-dieu-tricua-benh-nhan-dang-dieu-tri-thuoc-khangvitamin-k-tai-phong-kham-bv-tam-duc.html.
Nguyễn Quốc Kính, Tạ Mạnh Cường (2011), “Đánh giá hiệu quả điều trị bằng thuốc chống đông kháng Vitamin K ở người bệnh sau thay
van tim cơ học.”, Y học Việt Nam tháng 10 - số 2/2011; tr. 44 - 46.
Đôn Thị Thanh Thủy và cs (2016), Khảo sát hiệu quả điều trị của thuốc kháng vitamin K trên bệnh nhân rung nhĩ hoặc có van cơ học tại
bệnh viện Trưng Vương.http://timmachhoc.vn/ tong-hop-tu-nghien-cuu-tren-lam-sang/1308- khao-sat-hieu-qua-dieu-tri-cua-thuoc-khangvitamin-k-tren-benh-nhan-rung-nhi-hoac-covan-tim-co-hoc-tai-benh-vien-trung-vuong. html.
Hồ Huỳnh Quang Trí(2017) Đánh giá chất lượng của điều trị chống đông bằng thuốc kháng Vitamin K ở bệnh nhân rung nhĩ không do bệnh van tim.http://timmachhoc.vn/ tong-hop-tu-nghien-cuu-tren-lam-sang/1321- danh-gia-chat-luong-cua-dieu-tri-chongdong-bang-thuoc-khang-vitamin-k-o-benhnhan-rung-nhi-khong-do-benh-van-tim.html.
Phạm Gia Trung (2013) Đánh giá thực trạng điều trị bằng thuốc chống đông kháng vitamin K ở bệnh nhân sau thay van tim cơ học tại bệnh
viện Tim Hà Nội . Luận văn thạc sĩ.
Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e44S–e88S, doi: 10.1378/chest.11-2292, indexed in Pubmed: 22315269.
Cotté FE, Benhaddi H, Duprat-Lomon I, Doble A, Marchant N, Letierce A, Huguet M. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. Clin Ther. 2014 Sep 1;36(9):1160-8. doi: 10.1016/j. clinthera.2014.07.016. Epub 2014 Aug 21.
Hart RG, Pearce LA, Aguilar MI. Metaanalysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867.
Johnson JA. Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics. Circulation 2008; 118: 1383 - 1393.
Lader E, Martin N, Cohen G, et al.Warfarin therapeutic monitoring: is 70% time in the therapeutic range
the best we can do? J Clin Pharm Ther. 2012; 37: 375 - 377 .
Loeliger EA. Laboratory control, optimal therapeutic ranges and therapeutic quality control in oral anticoagulation. Acta Haematol.
; 74(3): 125 - 131, doi: 10.1159/000206187, indexed in Pubmed: 3938155.
Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G, Hurley JS, Pezzella S, Kaatz S: Quality of anticoagulation control
and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann
Pharmacother 2005, 39: 446 - 451.
Oldgren J, Healey JS, Ezekowitz M, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15400
emergency department patients in 46 countries: the RE-LY atrial fibrillation registry. Circulation 2014; 129: 1568 - 1576.
Rosendaal FR, Cannegi eter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb
Haemost. 1993; 69(3): 236 - 239, indexed in Pubmed: 8470047.
Sawicka - Powierza J, Buczkowski K, Chlabicz S, Gugnowski Z, Powierza K, Ołtarzewska AM. Quality control of oral anticoagulation
with vitamin K antagonists in primary care patients in Poland: a multi-centre study.Kardiol Pol. 2018; 76 (4): 764 - 769. doi: 10.5603/
KP.2018.0011. Epub 2018 Jan 9.
Shen AY, Chen W, Yao JF et al. Effect of race/ ethnicity on the efficacy of warfarin: potential implication for prevention of stroke in patients
with atrial fibrillation. CNS Drugs 2008; 22: 815 - 825.
Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel
CC, Patel MR, Califf RM, Fox KA, ROCKET AF Investigators: Impact of global geographic region on time in therapeutic range on warfarin
anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013, 2: e000067.
White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW: Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007, 167: 239 - 245.
Willey VJ , Bullano MF , Hauch O , et al . Management patterns and outcomes of patients with venous thromboembolism in the usual
community practice setting . Clin Ther . 2004 ; 26 (7): 1149 - 1159.
ACC/AHA/ESC guidelines: Fuster V et al. Circulation 2006;114:e257-354& Eur Heart J 2006; 27: 1979 - 2030.
| Published | 18-01-2025 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 61 (2020) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.2020.61.6 | |
| Keywords | Thuốc kháng vitamin K, thời gian trong ngưỡng trị liệu, chỉ số chuẩn hóa quốc tế, Rosendaal Vitamin K antagonists, time in therapeutic range, International Normalized Ratio, Rosendaal |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2020 Journal of Clinical Medicine Hue Central Hospital